Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS
mobile menu button

Articles

Page Path
HOME > Diabetes Metab J > Volume 46(5); 2022 > Article
Corrigendum
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kyuho Kim1,2, Henry N. Ginsberg3, Sung Hee Choi1,4
Diabetes & Metabolism Journal 2022;46(5):817-818.
DOI: https://doi.org/10.4093/dmj.2022.0295
Published online: September 19, 2022
  • 2,724 Views
  • 158 Download
  • 5 Web of Science
  • 5 Crossref
  • 6 Scopus

1Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

2Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

3Department of Preventive Medicine and Nutrition, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA

4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Copyright © 2022 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev
Full Article

Download PDF Download PDF

This corrects the article "New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins" on page 517.
Diabetes Metab J 2022;46:517-532. https://doi.org/10.4093/dmj.2022.0198
In this article Page 517, a part of abstract was corrected as follows:
Pemafibrate, the first selective peroxisome proliferator-activated receptor alpha (PPARα) modulator, showed a favorable benefit-risk balance in phase 2 trial, but the large clinical phase 3 trial (PROMINENT) was recently stopped for futility based on a late interim analysis.
In Page 521, a part of text was corrected as follows:
Nevertheless, considering that pemafibrate may prevent disease progression in non-alcoholic fatty liver disease (NAFLD) patients with hypertriglyceridemia, the possibility that of ASCVD risk reduction by pemafibrate in patients with NAFLD remains [57].
In Page 521-522, a part of text was corrected as follows:
The contrasting results for icosapent ethyl versus omega-3 carboxylic acids have led to a controversy focused on design differences between the comparator oils (placebos) in REDUCE-IT trial and STRENGTH. REDUCE-IT used mineral oil whereas STRENGTH used corn oil. Importantly, the REDUCE-IT investigators reported significant increases in LDL-C and CRP in the mineral oil group compared to icosapent ethyl-treated group [62]. That finding led to a cohort study, which was designed to mimic the REDUCE-IT trial; it showed that the contrasting CVD outcomes between the two trials could be partly explained by a difference in the effects of the comparator oils (mineral vs. corn), but not the active oils (EPA vs. EPA+DHA), on lipid traits and C-reactive protein [65]. Recently, a study of several ASCVD-related biomarkers in REDUCE-IT, conducted by the investigators themselves, showed that icosapent ethyl had minimal effects on those biomarkers, whereas levels increased among those allocated to mineral oil [66]. All together, these analyses suggest that the results of the REDUCE-IT trial must be interpreted with some caution.
In Page 524, heading was corrected from ‘IONIS-APO(a)Rx and IONIS-APO(a)LRx’ to ‘Apo(a) inhibitor’.
In Page 525, a part of text was added as follows:
Recently, the results of olpasiran, an siRNA to target LPA were reported. In a phase 1 trial involving participants with Lp(a) 70–199 nM or >200 nM, single doses of olpasiran at 3, 9, 30, 75, or 225 mg were administered. Plasma Lp(a) levels were reduced in a dose-responsive manner from 71% to 97%. Only one patient on olpasiran experienced an injection site reaction [118].
In addition, the results of SLN360, an siRNA to target LPA messenger RNA were reported. In a phase 1 trial involving participants with Lp(a) >60 mg/dL and no known CVD, single doses of SLN360 at 30, 100, 300, or 600 mg were administered. Plasma Lp(a) levels were reduced by 46% at a dose of 30 mg, 86% at 100 mg, 96% at 300 mg, and 98% at 600 mg, as compared with the 10% with the placebo. Low-grade injection site reactions and headache were common treatment-emergent adverse events [119].
In Page 525, a part of text was corrected as follows:
Indeed, few epidemiological studies showed increased mortality when plasma HDL-C was elevated [123,124]. In addition, RCTs with niacin and cholesteryl ester transfer protein inhibitors, in which HDL-C levels were significantly increased, failed to show a reduction in ASCVD risk [125,126].
In Page 525, a part of text was corrected as follows:
Lipid-free apoA1 triggers microsolubilization of cell membrane lipids, facilitating transfer of free cholesterol and phospholipids, after an interaction with the ATP-binding cassette transporter A1, to form nascent HDL particles [128,129]. These nascent HDL particles, after being remodeled by the lecithin cholesterol acyltransferase, transform into mature HDL particles. These mature HDL particles interact with the ATP-binding cassette transporter G1, ATPbinding cassette transporter G4, and scavenger receptor class B type 1 to mediate additional cholesterol efflux from the foam cells in the arterial wall [130,131].
In Page 526, a part of text was corrected as follows:
Pemafibrate, the first selective PPARα modulator, shows a favorable benefit-risk balance compared to fenofibrate in early phase trials but seems to have failed to reduce ASCVD in PROMINENT.
A corrected version of Fig. 1 and figure legend is attached.
A corrected version of Table 1 is attached. Olpasiran and SLN360 have been added in the table.
Majority of Corrigendum was done for clarifying the meaning of the sentence or paragraph. We apologize for any inconvenience that this may have caused.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table
      François Mach, Frank L.J. Visseren, Nilo B. Cater, Nejoua Salhi, Jarkko Soronen, Kausik K. Ray, Victoria Delgado, J. Wouter Jukema, Ulrich Laufs, Jose-Luis Zamorano, Emilio Ros, Jogchum Plat, Akos Gabor Gesztes, Lale Tokgozoglu, Chris Packard, Peter Libby
      Journal of Clinical Lipidology.2024;[Epub]     CrossRef
    • Engineered exosomes as a prospective therapy for diabetic foot ulcers
      Lifei Guo, Dan Xiao, Helin Xing, Guodong Yang, Xuekang Yang
      Burns & Trauma.2024;[Epub]     CrossRef
    • Lipidomic profiling in patients with familial hypercholesterolemia: Abnormalities in glycerolipids and oxysterols
      Shiva Ganjali, Vladimiro Cardenia, Ambra Bonciolini, Raul D. Santos, Khalid Al-Rasadi, Amirhossein Sahebkar
      Clinical Biochemistry.2024; 131-132: 110812.     CrossRef
    • Olezarsen and Plozasiran in Dyslipidemia Management: A Narrative Review of Clinical Trials
      Gbolahan Olatunji, Ikponmwosa Jude Ogieuhi, Emmanuel Kokori, Ajekiigbe Victor Oluwatomiwa, Oluwafemi Isaiah Ajimotokan, God-dowell O. Odukudu, Samuel Owolabi, Sopuruchukwu Anyacho, Chijindu Nnaemeka Nwakama, Adetola Emmanuel Babalola, Franklin Andibanbang
      High Blood Pressure & Cardiovascular Prevention.2024;[Epub]     CrossRef
    • Remnant Cholesterol, a Valuable Biomarker for Assessing Arteriosclerosis and Cardiovascular Risk: A Systematic Review
      Xiang Chen, Li-Hua Li
      Cureus.2023;[Epub]     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite this Article
      Cite this Article
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
      Diabetes Metab J. 2022;46(5):817-818.   Published online September 19, 2022
      DOI: https://doi.org/10.4093/dmj.2022.0295
      Close
    • XML DownloadXML Download
    Related articles
    New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
    New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
    Kim K, Ginsberg HN, Choi SH. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Diabetes Metab J. 2022;46(5):817-818.
    DOI: https://doi.org/10.4093/dmj.2022.0295.
  • Download citation ↓
    • Diabetes Metab J : Diabetes & Metabolism Journal
    © Korean Diabetes Association.
    Close layer
    Email address
    Sign up for the DMJ newsletter—
    what matters in science, free to your inbox daily.
    TOP